Mifomet

Metformin Hydrochloride / Sitagliptin, the active ingredient in Mifomet, is a Biguanide and DPP‑4 inhibitor presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adult patients.

GNH USA supplies Mifomet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Mifomet is manufactured under GMP conditions and distributed through a network that supports timely delivery to healthcare providers.

Mifomet combines metformin and sitagliptin to improve glycemic control in type 2 diabetes.

- Type 2 diabetes mellitus: improves blood glucose control and reduces HbA1c when added to diet, exercise, and other antidiabetic agents. - Inadequate response to metformin alone: provides additional glucose‑lowering effect through DPP‑4 inhibition. - Combination with insulin therapy: helps lower required insulin dose while maintaining target glycaemic levels.

Mifomet may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: loose stools occurring especially during treatment initiation. - Headache: mild to moderate intensity. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain. - Hepatic dysfunction: signs of liver injury such as jaundice. - Anaphylactic reaction: rare systemic allergic response requiring immediate medical attention.

Before prescribing Mifomet, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Hepatic function: use with caution in patients with liver disease; discontinue if hepatic failure occurs. - Lactic acidosis risk: discontinue promptly if symptoms of metabolic acidosis develop. - Pregnancy and lactation: prescribe only if the potential benefit outweighs potential risk to the fetus or infant. - Drug interactions: review concomitant medications for agents that may affect renal clearance or increase hypoglycaemia risk. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Mifomet can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Severe renal impairment: increased metformin accumulation may precipitate lactic acidosis. - Co‑administration with other DPP‑4 inhibitors: additive pharmacologic effect and risk of adverse reactions. - Iodinated contrast agents: may cause acute kidney injury, necessitating temporary discontinuation of metformin.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened risk of hypoglycaemia; dose adjustments may be needed. - Cimetidine: can raise sitagliptin plasma concentrations. - Loop diuretics (e.g., furosemide): may affect metformin renal clearance. - Beta‑blockers: may mask hypoglycaemia symptoms. - Corticosteroids: can increase blood glucose levels, potentially reducing drug efficacy.